MARKET

MACK

MACK

Merrimack Pharma
NASDAQ
14.73
+0.02
+0.14%
Opening 10:21 04/25 EDT
OPEN
14.71
PREV CLOSE
14.71
HIGH
14.73
LOW
14.71
VOLUME
6.37K
TURNOVER
0
52 WEEK HIGH
15.89
52 WEEK LOW
11.53
MARKET CAP
214.05M
P/E (TTM)
-178.3293
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MACK last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at MACK last week (0408-0412)?
Weekly Report · 04/15 09:59
Weekly Report: what happened at MACK last week (0401-0405)?
Weekly Report · 04/08 10:01
Weekly Report: what happened at MACK last week (0325-0329)?
Weekly Report · 04/01 10:01
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
TipRanks · 03/27 21:13
Merrimack receives $225M milestone payment from Ipsen
Merrimack Pharmaceuticals, Inc. Receives $225M milestone payment from Ipsen. Healthcare Merrimack receives approval to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas. The company has announced a special meeting of stockholders on May 10, 2024.
Seeking Alpha · 03/27 20:36
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
The company has received a $225 million payment which was due from Ipsen, S.A. To market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas. Merrimack announced a special meeting of stockholders on May 10, 2024 to approve a liquidating dividend.
Benzinga · 03/27 20:34
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Pharmaceuticals, Inc. Announced it has received a $225 million payment from Ipsen, S.A. The payment was due as a result of approval of ONIVYDE to market on the pancreas. Merrimack has announced a special meeting of stockholders on May 10, 2024 to approve a Plan of Dissolution. The company is entitled to $450.0 million in contingent milestone payments.
Barchart · 03/27 15:30
More
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Webull offers Merrimack Pharmaceuticals Inc stock information, including NASDAQ: MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.